EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gain Therapeutics's enterprise value is $33.02 Mil.
Gain Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-21.34 Mil. Therefore, Gain Therapeutics's EV-to-EBITDA for today is -1.55.
The historical rank and industry rank for Gain Therapeutics's EV-to-EBITDA or its related term are showing as below:
GANX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.35 Med: -1.35 Max: 0.21
Current: -1.55
During the past 6 years, the highest EV-to-EBITDA of Gain Therapeutics was 0.21. The lowest was -42.35. And the median was -1.35.
GANX's EV-to-EBITDA is ranked worse than 100% of 452
companies
in the Biotechnology industry
Industry Median: 9.27
vs GANX: -1.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Gain Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Gain Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gain Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Gain Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gain Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gain Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gain Therapeutics's EV-to-EBITDA falls into.
Gain Therapeutics's current Enterprise Value is $33.02 Mil.
Gain Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gain Therapeutics (NAS:GANX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gain Therapeutics's PE Ratio (TTM) for today is calculated as:
Gain Therapeutics's share price for today is $1.63.
Gain Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Gain Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GANX has been successfully added to your 